Literature DB >> 23275799

MPTP mouse models of Parkinson's disease: an update.

Gloria E Meredith1, David J Rademacher.   

Abstract

Among the most widely used models of Parkinson's disease (PD) are those that employ toxins, especially 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Depending on the protocol used, MPTP yields large variations in nigral cell loss, striatal dopamine loss and behavioral deficits. Motor deficits do not fully replicate those seen in PD. Nonetheless, MPTP mouse models mimic many aspects of the disease and are therefore important tools for understanding PD. In this review, we will discuss the ability of MPTP mouse models to replicate the pathophysiology of PD, the mechanisms of MPTP-induced neurotoxicity, strain differences in susceptibility to MPTP, and the models' roles in testing therapeutic approaches.

Entities:  

Mesh:

Year:  2011        PMID: 23275799      PMCID: PMC3530193          DOI: 10.3233/JPD-2011-11023

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  161 in total

1.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining.

Authors:  N A Tatton; S J Kish
Journal:  Neuroscience       Date:  1997-04       Impact factor: 3.590

2.  Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons.

Authors:  Suizhen Lin; Xing Wei; Yong Xu; Chong Yan; Richard Dodel; Yuqin Zhang; Junyi Liu; James E Klaunig; Martin Farlow; Yansheng Du
Journal:  Life Sci       Date:  2003-02-21       Impact factor: 5.037

3.  Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.

Authors:  Xichuan Teng; Takashi Sakai; Li Liu; Rika Sakai; Ryuji Kaji; Kiyoshi Fukui
Journal:  J Neurochem       Date:  2006-05       Impact factor: 5.372

4.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

5.  The parkinsonian toxin MPTP: action and mechanism.

Authors:  Serge Przedborski; Vernice Jackson-Lewis; Ruth Djaldetti; Gabriel Liberatore; Miquel Vila; Slobodanka Vukosavic; Gabrielle Almer
Journal:  Restor Neurol Neurosci       Date:  2000       Impact factor: 2.406

Review 6.  Antiparkinsonian drugs and their neuroprotective effects.

Authors:  Yoshihisa Kitamura; Jun-Ichi Kakimura; Takashi Taniguchi
Journal:  Biol Pharm Bull       Date:  2002-03       Impact factor: 2.233

7.  Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain.

Authors:  P Chan; L E DeLanney; I Irwin; J W Langston; D Di Monte
Journal:  J Neurochem       Date:  1991-07       Impact factor: 5.372

8.  Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.

Authors:  I Kurkowska-Jastrzebska; E Bałkowiec-Iskra; A Ciesielska; I Joniec; A Cudna; M M Zaremba; A Członkowski; A Członkowska
Journal:  Int Immunopharmacol       Date:  2009-03-13       Impact factor: 4.932

Review 9.  A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.

Authors:  Gloria E Meredith; Glenda M Halliday; Susan Totterdell
Journal:  Parkinsonism Relat Disord       Date:  2004-06       Impact factor: 4.891

10.  Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage.

Authors:  Celine Perier; Kim Tieu; Christelle Guégan; Casper Caspersen; Vernice Jackson-Lewis; Valerio Carelli; Andrea Martinuzzi; Michio Hirano; Serge Przedborski; Miquel Vila
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

View more
  128 in total

1.  Are striatal tyrosine hydroxylase interneurons dopaminergic?

Authors:  Harry S Xenias; Osvaldo Ibáñez-Sandoval; Tibor Koós; James M Tepper
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

2.  Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.

Authors:  Rosa Calvello; Antonia Cianciulli; Giuseppe Nicolardi; Francesco De Nuccio; Laura Giannotti; Rosaria Salvatore; Chiara Porro; Teresa Trotta; Maria Antonietta Panaro; Dario Domenico Lofrumento
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-16       Impact factor: 4.147

3.  Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.

Authors:  Mrittika Chattopadhyay; Anindya Roy Chowdhury; Ting Feng; Charles-Antoine Assenmacher; Enrico Radaelli; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2019-05-20       Impact factor: 5.157

Review 4.  Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?

Authors:  David A Loeffler; Peter A LeWitt; Dianne M Camp
Journal:  Mov Disord       Date:  2016-07-14       Impact factor: 10.338

5.  Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Neha Srivastava; Rakesh Shukla; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

6.  Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Authors:  K Xu; D G Di Luca; M Orrú; Y Xu; J-F Chen; M A Schwarzschild
Journal:  Neuroscience       Date:  2016-02-22       Impact factor: 3.590

Review 7.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 8.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

9.  Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Aderbal S Aguiar; Fabrine S M Tristão; Majid Amar; Caroline Chevarin; Laurence Lanfumey; Raymond Mongeau; Olga Corti; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-04-16       Impact factor: 3.911

10.  FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.

Authors:  Joseph R Patterson; Elizabeth J Kim; John L Goudreau; Keith J Lookingland
Journal:  Brain Res       Date:  2016-08-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.